ASH 2024
Posted: Tue Nov 05, 2024 3:06 pm
I see these two. Do you see more?
[ 1 ]
Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
Result Type: Paper
Number: 4590
Presenter: Rami Komrokji
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Search Result:
... are relapsed or refractory to or ineligible for erythropoiesis-stimulating agents (ESA) based on the results of the pivotal phase 3 IMerge trial (NCT02598661). IMerge demonstrated a clinically meaningful and statistically significant RBC-transfusion independence (TI) rate for imetelstat versus placebo for the ...
Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
Result Type: Paper
Number: 352
Presenter: Uwe Platzbecker
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS
Time and Location:
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Ballroom 20AB (San Diego Convention Center)
Search Result:
... patients who were relapsed or refractory to or ineligible for erythropoiesis-stimulating agents (ESA) based on the results of the pivotal IMerge trial (NCT02598661). IMerge demonstrated significant and durable efficacy of IME (n=118) versus placebo (n=60) for ≥8-week, ≥24-week, and ≥1-year RBC-transfusion ...
[ 1 ]
Initial Results from the QTc Substudy of the IMerge Phase 3 Trial Demonstrate Clinically Meaningful Efficacy, Manageable Safety, and Absence of Proarrhythmic Risk in Patients with Lower-Risk Myelodysplastic Syndromes Who Received Prior Therapies Beyond Erythropoiesis Stimulating Agents
Result Type: Paper
Number: 4590
Presenter: Rami Komrokji
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III
Time and Location:
Monday, December 9, 2024: 6:00 PM-8:00 PM
Halls G-H (San Diego Convention Center)
Search Result:
... are relapsed or refractory to or ineligible for erythropoiesis-stimulating agents (ESA) based on the results of the pivotal phase 3 IMerge trial (NCT02598661). IMerge demonstrated a clinically meaningful and statistically significant RBC-transfusion independence (TI) rate for imetelstat versus placebo for the ...
Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes
Result Type: Paper
Number: 352
Presenter: Uwe Platzbecker
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS
Time and Location:
Saturday, December 7, 2024: 4:00 PM-5:30 PM
Ballroom 20AB (San Diego Convention Center)
Search Result:
... patients who were relapsed or refractory to or ineligible for erythropoiesis-stimulating agents (ESA) based on the results of the pivotal IMerge trial (NCT02598661). IMerge demonstrated significant and durable efficacy of IME (n=118) versus placebo (n=60) for ≥8-week, ≥24-week, and ≥1-year RBC-transfusion ...